Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Tel-Aviv Sourasky Medical Center
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
43Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00295035CT.gov Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Colon Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Celecoxib (this asset) | Tel-Aviv Sourasky Medical Center | P3 | B · 58 |
| Tranexamic Acid | Assaf-Harofeh Medical Center | P4 | BB |
| Fluorouracilum | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P2 | BB |
| Regorafenib | City of Hope Medical Center | P2 | B |
| Irinotecan | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P2 | B |
| Oxaliplatin | Second Affiliated Hospital, School of Medicine, Zhejiang University | P2 | B |
| Cetuximab | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P2 | B |
| Nivolumab | M.D. Anderson Cancer Center | P1/2 | B |
| Volitinib | National Cancer Institute (NCI) | P2 | CCC |
+26 more in the Malignant Colon Neoplasm cohort
Other indications for Celecoxib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteoarthritis, Hip | — | P4 | BB · 71 |
| Osteoarthritis, Knee | — | P4 | BB · 69 |
| Bipolar Depression | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Tranexamic AcidAssaf-Harofeh Medical CenterBB
- FluorouracilumFondazione Policlinico Universitario Agostino Gemelli IRCCSBB
- RegorafenibCity of Hope Medical CenterB
- IrinotecanFondazione Policlinico Universitario Agostino Gemelli IRCCSB
- OxaliplatinSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityB
Citation
Floatz Terminal. Celecoxib in Malignant Colon Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/celecoxib-malignant-colon-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →